The closure of the R-Pharm plant in Germany threatens the supply of tuberculosis drugs to the Russian Federation

The closure of the R-Pharm plant in Germany threatens to disrupt the supply of a unique anti-tuberculosis drug to Russia. This was reported by the “Without Prescription” Telegram channel.

The German subsidiary of R-Pharm, R-Pharm Germany GmbH, declared bankruptcy and closed the site in Bavarian Illertissen, where Deltiba (delamanid) was produced for the treatment of multidrug-resistant tuberculosis.

In January, R-Pharm agreed with the Federal Center for Planning and Organization of Medicinal Provision of Citizens on the supply of 75.4 thousand packages of the drug in the amount of 523.6 million rubles. At the same time, already in July the company announced that it was ready to supply only 15 thousand packages and warned that the supply of the drug would not be available in 2027

Delamanid was developed by the Japanese Otsuka Pharmaceutical and has been included in the WHO list of essential medicines since 2015. It is used when standard anti-TB drugs do not work. In Russia, Deltiba is included in the list of Vital and Essential Medicines (VED), and the state guarantees its availability to patients. However, after the closure of the R-Pharm Germany plant, Russia loses the only supply channel for this drug, and it is not produced in the Russian Federation.